Evidence map›Paper›PMID 41521560›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Dual-targeting CD133/PD-L1 CAR-T plus αPD-1 overcomes immunosuppressive microenvironment and enhanced by radiation pre-conditioning.

Zhuoran Yao, Kai Kang, Pei-Heng Li, Limei Yin, Ruizhan Tong, Linglu Yi, Yonghong Song, Ren Luo, Yijun Wu, Shanghai Liu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhuoran YaoDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Kai KangDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Pei-Heng LiDivision of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Limei YinDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Department of Health Management & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Ruizhan TongDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Linglu YiLaboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Yonghong SongChengdu Brilliant Harpoon Co., Ltd, Chengdu 610200, China.
Ren LuoDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Yijun WuDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Shanghai LiuDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Zichong PengDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Xianming MoLaboratory of Stem Cell Biology, West China Hospital, Sichuan University, Chengdu 610041, China.
Wenbo WangDepartment of Oncology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Jianxin XueDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: radjianxin@163.com.
You LuDivision of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: radyoulu@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innovative chimeric antigen receptor (CAR) T cell designs and combinational approaches are needed for enhancing therapeutic effectiveness in solid tumors. We developed and assessed a novel dual-targeting CAR-T therapy that combines an αPDL1.CD28 chimeric receptor with a second-generation αCD133 CAR to target CD133

Indexed as

AC133 AntigenB7-H1 AntigenImmunotherapy, AdoptiveNeoplasmsProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansMiceXenograft Model Antitumor AssaysAC133 AntigenB7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Chimeric Antigenchimeric antigen T cell receptorE-cadherinPD-L1/PD-1 pathwayradiotherapytissue-resident memory T cells

Identifiers

PMID41521560
PMCPMC12974209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.